
COVID Rebound Can Happen Even without Paxlovid
Concerns about Paxlovid rebound are preventing some doctors from prescribing the lifesaving drug and some high-risk patients from taking it
Lauren Gravitz is a science journalist in San Diego, Calif., who has contributed to Nature, NPR, the Washington Post, MIT Technology Review and the Economist, among other publications. She is a 2021–2022 Knight Science Journalism Project Fellow at the Massachusetts Institute of Technology.
Concerns about Paxlovid rebound are preventing some doctors from prescribing the lifesaving drug and some high-risk patients from taking it
A special package highlights problems and solutions
Despite the vast resources aimed at finding ways to detect cancer early, more needs to be done
Various approaches are approved for treating blood cancers and a few rare disorders—they may soon become standard care
The two conditions share many traits, but the connection has been largely overlooked until now
Many people on the spectrum take multiple medications, which can lead to serious side effects and may not even be effective
Tailoring cancer treatment to individual and evolving tumours is the way of the future, but scientists are still hashing out the details
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account